Antineoplastic Drug Exposure in an Ambulatory Setting: a Pilot Study
Published Date:2015 Mar-Apr
Source:Cancer Nurs. 38(2):111-117.
Pubmed Central ID:PMC4232489
Funding:P30CA46592/CA/NCI NIH HHS/United States
R00 NR010750/NR/NINR NIH HHS/United States
R00NR010750/NR/NINR NIH HHS/United States
T42OH008455/OH/NIOSH CDC HHS/United States
Exposure to antineoplastic drugs confers health risks to workers, yet little is known about the exposure after a drug spill. Nor has the relationship between exposure and organizational factors such as staffing and work environment been studied.
To evaluate drug spills prospectively using biological measures and correlate drug spills with organizational factors.
Prospective questionnaires with 8-hour timed urine samples were collected from nursing and pharmacy personnel who reported a drug spill in one academic health center's infusion center. Urine was collected similarly from workers who did not report a spill. Liquid chromatography tandem mass spectrometry techniques identified detectable drug levels. After the prospective sampling period, workers were surveyed on workloads, practice environment, and safety behaviors.
From 81 eligible individuals, 40 participated in the prospective study and 19 completed retrospective questionnaires. Four spills were reported by 9 personnel as multiple employees were exposed to drug spills. Four participants who reported a spill showed detectable levels of antineoplastic drugs. Four participants who did not report a spill had detectable levels of docetaxel. Compared with respondents who did not report a spill, collegial relations with physicians were significantly poorer for workers who reported spills.
The study protocol successfully captured drug spill reports and biological samples. Workers have detectable levels of antineoplastic drugs through both drug spills and environmental contamination.
text/plain image/gif image/jpeg
You May Also Like: